Maen Abdelrahim, MD
Medical Oncology Physician · Houston, TX
Maen Abdelrahim, MD is a medical oncology physician with a practice address in Houston, Texas, and NPI 1518227735, issued on May 22, 2012. Check the license (Texas Q1781, as entered in NPPES) on the Texas Medical Board; the Medicare figures below come from public CMS files.
- Name
- Maen Abdelrahim
- Credential
- MD
- Primary taxonomy
- Medical Oncology Physician 207RX0202X
- License numbers
- Q1781 TX
BP10043067 TX
Self-reported in NPPES; status is on the state search - Practice location
- 6445 Main Street, Opc24, Houston, TX 77030
- Phone
- (713) 441-9948
- Enumerated
- May 22, 2012
- Record last updated
- Mar 17, 2018 (not updated in 8 years: call before relying on the address or phone)
- Medicaid ID
- 374923601 TX
- Medicare enrollment
- Enrolled (PECOS I20170824000638); accepts Medicare assignment
- Medical or professional school
- Texas A & M University System, Hsc, College Of Medicine, 2012
- Telehealth
- Offers telehealth (CMS)
- Entity
- Type 1 · individual
8 nearest medical oncology physician records → All 547 in Texas → Look up another NPI →
Verify Maen Abdelrahim in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersTexas Medical Board
Search for license Q1781Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
45% fewer Medicare Part D claims than the average medical oncology physician in 2024
390 Medicare Part D claims for 96 beneficiaries, against an average of 703 among the 4,230 providers of this specialty who prescribed in Part D. Brand-name drugs were 20% of claims. 36 claims were for opioids.
Most prescribed
- Prochlorperazine Maleate42 claims
- Ondansetron Odt39 claims
- Hydrocodone-Acetaminophen33 claims
- Lenvima26 claims
- Imatinib Mesylate22 claims
- Ondansetron Hcl18 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
Industry payments in 2024: $355,741.90
204 payments; by number, the most common kind was travel and lodging; the largest payer was Takeda Pharmaceuticals U.S.A., Inc. The 3,343 providers of this specialty with any payment received $11,773.47 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.
Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.
Bills Medicare through 2 group practices
- Houston Methodist Specialty PhysiciansHouston, TX
- Tmh Physician Associates PLLCSugar Land, TX
Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).
Maen Abdelrahim among 547 medical oncology physician records in Texas
Maen Abdelrahim, MD is one of 547 medical oncology physician records with a practice address in Texas. 85% of them appear in a Medicare file (Part D prescribing, MIPS, Open Payments or Medicare group billing); this one does. Its NPI, issued in 2012, is newer than 82% of them.
- NPI issued2012 · 82% of these records are older, 15% newer
- In a Medicare fileYes · 85% of these records are
- In the CMS Doctors and Clinicians fileYes · 76% of these records are
- Graduated2012 · median 2000 among the 414 with a school on file
- Record last updated2018 · 62% of these records were not updated in five years or more
Source: CMS NPPES, file of Aug 9, 2026, every record with primary taxonomy 207RX0202X and a Texas practice address; Medicare files: CMS Part D Prescribers 2024, MIPS 2023, Open Payments 2024, Doctors and Clinicians (data.cms.gov).
Medical Oncology Physician providers in Texas
There are 547 medical oncology physician records in Texas.
All 547 in Texas → Every provider in Houston → Medical Oncology Physician nationwide →
The 8 medical oncology physician records with the nearest ZIP codes
- Matthew Ellis, MD PHDHouston, TX 770301669495685
- Daniel Epner, M.D.Houston, TX 770301083637151
- Jianjun Gao, M.D.Houston, TX 770301053356873
- Christopher Garrett, MDHouston, TX 770301861417115
- Maura Gillison, MDHouston, TX 770301760436927
- Anneliese Gonzalez, M.D.Houston, TX 770301245234889
- Kirk Heyne, MDHouston, TX 770301346227816
- Milind Javle, MDHouston, TX 770301831196252
Common questions
What is Maen Abdelrahim, MD's NPI number?
Maen Abdelrahim, MD's National Provider Identifier (NPI) is 1518227735, issued on May 22, 2012. An NPI identifies a provider in billing; it is not a license.
Where is Maen Abdelrahim, MD located?
The NPPES record lists a practice address at 6445 Main Street, Opc24, Houston, TX, 77030. Phone: (713) 441-9948. Providers update this record themselves, so call before visiting.
How can I verify Maen Abdelrahim, MD's license?
NPPES lists Texas license number Q1781, as entered by the provider. Search the Texas Medical Board at https://profile.tmb.state.tx.us/Search.aspx. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Maen Abdelrahim, MD prescribe under Medicare Part D?
In 2024, Maen Abdelrahim, MD had 390 Medicare Part D claims for 96 beneficiaries; the average among medical oncology physician prescribers was 703. Part D covers Medicare prescriptions only.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.